Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.41 |
| ▸ | FABP1 | P07148 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3562326 | 0.87 | SLC16A3 (0.53) | TSHRALDH1A1PTGESALOX5MAPT | |
| SCHEMBL3554681 | 0.83 | SLC16A3 (0.55) | TSHRPTGESALOX5SLC16A3 | |
| SCHEMBL3553576 | 0.83 | ALOX5 (0.47) | ALDH1A1PTGESALOX5MAPTSLC16A3 | |
| SCHEMBL3555271 | 0.82 | ALOX5 (0.59) | ALDH1A1HPGDPTGESALOX5MAPT | |
| SCHEMBL3558519 | 0.81 | ALOX5 (0.45) | ALDH1A1PTGESALOX5MAPTSLC16A3 | |
| SCHEMBL3562738 | 0.81 | ALOX5 (0.45) | ALDH1A1HPGDPTGESALOX5MAPT | |
| SCHEMBL3555107 | 0.80 | ALOX5 (0.48) | ALDH1A1PTGESALOX5MAPT | |
| SCHEMBL3554230 | 0.80 | ALOX5 (0.60) | ALDH1A1PTGESALOX5MAPTSMN1; SMN2 | |
| SCHEMBL3557949 | 0.80 | ALOX5 (0.60) | ALDH1A1PTGESALOX5MAPTSMN1; SMN2 | |
| SCHEMBL3555258 | 0.80 | SLC16A3 (0.53) | ALDH1A1PTGESALOX5MAPTSLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | TSHR 3483/4885ALDH1A1 61/4885HPGD 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.